Determination Imatinib Mesylate on Obelisc R Column

Separation type: Liquid Chromatography Ion Exclusion View on

High Performance Liquid Chromatography (HPLC) Method of Imatinib mesylate. Imatinib mesylate is effective in treating chronic myeloid leukemia and metastatic gastrointestinal stromal tumors. It is classified as a signal transduction inhibitor. It can be retained on an Obelisc R column, which has both positive and negative ion-pairs embedded in the stationary phase, allowing for the fine tuning and separation of a wide range of compounds with different ionic properties. Imatinib mesylate can be determined isocratically using a simple MS-compatible mobile phase of acetonitrile (ACN) and water with Ammonium Formate (AmFm) buffer and detected by UV at 270nm, ELSD, CAD or LC/MS.


Column Obelisc R, 4.6x150 mm, 5 µm, 100A
Mobile Phase MeCN -50%
Buffer Ammonium Formate pH 3.0 - 50 mM
Flow Rate 1.0 ml/min
Detection UV 270nm


Class of Compounds  Drug
Analyzing Compounds Imatinib Mesylate
Application Analytes:
Imatinib mesylate